Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
Eisenberger
M A
MA
Division of Medical Oncology, Johns Hopkins Oncology Center (Mid-Atlantic Oncology Program and Southwest Oncology Group), Baltimore, MD 21287-8936.
Crawford
E D
ED
Wolf
M
M
Blumenstein
B
B
McLeod
D G
DG
Benson
R
R
Dorr
F A
FA
Benson
M
M
Spaulding
J T
JT
D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D012044:Regression Analysis; D016019:Survival Analysis